Aerie Pharmaceuticals

YTD

ALL

Why Robinhood?

You can watch AERI and buy or sell other stocks, ETFs, and their options commission-free!

About AERI

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105.

CEO

David J. Endicott, MBA

CEODavid J. Endicott, MBA

Employees

—

Employees—

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

2005

Founded2005

Employees

—

Employees—

AERI Key Statistics

Market cap

753.62M

Market cap753.62M

Price-Earnings ratio

-19.89

Price-Earnings ratio-19.89

Dividend yield

—

Dividend yield—

Average volume

515.67K

Average volume515.67K

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$15.37

52 Week high$15.37

52 Week low

$4.81

52 Week low$4.81

People also own

Based on the portfolios of people who own AERI. This list is generated using Robinhood data, and it’s not a recommendation.